Navigation Links
Nektar Therapeutics Reports Third Quarter 2009 Financial Results
Date:11/4/2009

ical development programs.

Revenue for the three month period ended September 30, 2009 was $10.2 million compared to revenue of $21.4 million in the third quarter of 2008. Revenue year-to-date September 30, 2009 was $32.9 million as compared to revenue of $61.8 million in the same period in 2008. This decrease in revenue is largely the result of lower contract research and manufacturing revenues primarily resulting from the sale of certain of the company's pulmonary assets to Novartis which occurred on December 31, 2008.

Cash, cash equivalents, and short-term investments at September 30, 2009 were $275.7 million. Not included in this cash balance is the cash payment of $125 million received from AstraZeneca in October 2009 as a result of the collaboration for NKTR-118 and NKTR-119.

Conference Call to Discuss Third Quarter 2009 Financial Results

A conference call to review results will be held today, Wednesday, November 4, 2009 at 2 PM Pacific Time.

Details are below:

Howard Robin, president and chief executive officer, and John Nicholson, chief financial officer, will host a conference call beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT) on Wednesday, November 4, 2009.

To access the conference call, follow these instructions:

Dial: 866-356-3095 (U.S.); 617-597-5391 (international)

Passcode: 27967367

An audio replay will also be available shortly following the call through Wednesday, November 18, 2009 and can be accessed by dialing 888-286-8010 (U.S.); or 617-801-6888 (international) with a passcode of 60261022.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
3. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
4. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
5. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. Nektar Therapeutics Reports First Quarter 2009 Financial Results
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
11. Nektar Announces Retirement of Irwin Lerner from Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...rstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), anno...to its shareholders, discussing the Company,s acqu...uticals Holdings, Inc. (CHBP), an integrated bio-p...ic of China. The merger gives NeoStem a controllin...td., CHBP,s primary operating subsidiary and a pro...
(Date:11/19/2009)... Aegera Therapeutics Inc. announced today the dosi...tudy of AEG35156, a targeted antisense therapeutic...dications. ,, The study, entitled "An Open-Labe...or of Apoptosis (XIAP) Antisense AEG35156 Given in...cin in AML Following Failure of a Single Standard ...
(Date:11/19/2009)...r 19 AFFiRiS AG will focus its,Alz...at an unexpectedly early,stage of development: the...hase II clinical trial early in 2010. This decisio...n of two Phase I trials with the candidates,AD01 a...e first interim,analysis of the secondary endpoint...
(Date:11/18/2009)... postage stamp that can sniff out poisonous gases ... reported in the Sept. 13 issue of the journal Na...he University of Illinois have developed an artifi...trial chemicals (TICs) that is simple, fast and in...ensor array could be useful in detecting high expo...
Breaking Biology Technology:NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
...nding of Operations Outside the US In ..., Md., Nov. 6 Northwest,Biotherapeutics, Inc. (OT...,announced that it has obtained US$1.65 million in...y Notes (the "Notes") with SDS Capital Group SPC,L...Private Investors"). A,significant portion of the ...
...nDance Technologies, Inc.,a provider of innovative...,disease research, today announced that it has shi...chment application to The Genome Center (GC) at,th...Louis, a world leader,in genomics research., Unde...nce will provide,its new RDT 1000 and expert train...
...lik, Inc.,(Nasdaq: TELK ) reported a net loss of ...arter ended September 30, 2008, compared with a ne...he comparable period in 2007. The,$8.0 million net...d to,corporate and municipal notes investments wit...ties, which is reflected in interest and other inc...
Other Biology Technology:Northwest Secures US$1.65 Million Debt Financing 2Northwest Secures US$1.65 Million Debt Financing 3Northwest Secures US$1.65 Million Debt Financing 4RainDance Technologies Delivers RDT 1000, Sequence Enrichment Solution to The Genome Center at Washington University School of Medicine in St. Louis 2Telik Announces Financial Results for 2008 Third Quarter 2Telik Announces Financial Results for 2008 Third Quarter 3Telik Announces Financial Results for 2008 Third Quarter 4
(Date:11/19/2009)...year, multi-institutional effort co-led by three C...minated today in publication of a landmark series ...precedented detail the DNA sequence of maize ( Zea...by North American consumers, is one of the world,s...ultural crop grown in the United States, represent...
(Date:11/19/2009)... Sustainable farming, initially adopted to preserv...ay a role in maintaining a healthy climate, accord...ak Ridge and Los Alamos national laboratories. , ...potential of the earth,s soils to sequester carbon...ces could greatly reduce U.S. carbon emissions by ...
(Date:11/19/2009)...innati professor of paleontology in the McMicken C...oote of the University of Chicago publish their re...r paper, "Epicontinental Seas Versus Open-Ocean Se...ation." , For many years, paleobiological resear...ve focused on charting the many ups (evolutionary ...
Breaking Biology News(10 mins):Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4ORNL, Los Alamos pioneer new approach to assist scientists, farmers 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 3Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 2Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 3Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 4Neurocrine Biosciences Secures Committed Equity Financing Facility 14065 1Neurocrine Biosciences Secures Committed Equity Financing Facility 14065 2Neurocrine Biosciences Secures Committed Equity Financing Facility 14065 3FDA Approves Vaccines for 2009 H1N1 Influenza Virus 57274 1FDA Approves Vaccines for 2009 H1N1 Influenza Virus 57274 2FDA Approves Vaccines for 2009 H1N1 Influenza Virus 57274 3Celiac Disease May Raise Risk of Dying 57272 1
...struction can be significantly improved to reduce ...tter resist high winds and hurricanes in residenti...ure professor Rima Taher, PhD. Taher, who is also...ersey School of Architecture. Courses taught by he...ith guidelines and recommendations for better desi...
...ow hepatitis C infection causes fatty liver a bui... life-threatening diseases such as cirrhosis and l...ate School of Public Health and School of Medicine... 9 online issue of Hepatology , shows that an enz..., fatty acid synthase (FAS), was highly elevated i...
...bese men should consider losing weight if they wan...al conference of the European Society of Human Rep... Dr. A Ghiyath Shayeb, from the University of Aber...wn that men with a higher body mass index (BMI) ha...ortion of abnormal sperm. , Dr. Shayeb and collea...
Other Biology News:NJIT architect professor advocates best-building practices for high wind regions 2Hepatitis C virus may need enzyme's help to cause liver disease 2Obese men have less semen, more sperm abnormalities, and should lose weight before trying for a baby 2
Anti-Bunyavirus (G1) Monoclonal Antibody, Unconjugated, Clone 8C2.1 from CHEMICON
Rabbit Anti-BI-1 Polyclonal Antibody, Unconjugated from BioVision
Capped Xef-1 RNA 0.05 ml from Ambion
Human TIMP-1 ELISpot Kit from R&D Systems
Biology Products: